|
- Treatment in Advanced NSCLC | LIBTAYO® (cemiplimab-rwlc)
or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene LIBTAYO may be used as your first treatment: In combination with chemotherapy that contains a platinum medicine, or alone if your tumor tests positive for high “PD-L1 ”
- LIBTAYO works with your immune system to help treat advanced . . .
LIBTAYO may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor
- How Libtayo Works for Non-Small-Cell Lung Cancer - WebMD
Libtayo may also be used along with a platinum-based chemotherapy as an initial (first-line) treatment for advanced or metastatic NSCLC that does not have other targetable mutations of EGFR, ALK
- LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC
LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic 1 Review combination therapy data
- Libtayo (cemiplimab-rwlc) - OHSU
Patient has recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease with no evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; AND
- Libtayo® (cemiplimab) Plus Chemotherapy Results . . . - BioSpace
The five-year results for Libtayo plus chemotherapy presented at WCLC add to the breadth of long-term data for Libtayo in advanced NSCLC, including five-year outcomes from the EMPOWER-Lung 1 trial that were presented at WCLC 2024 confirming durable survival benefit as monotherapy
- Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation
- Cemiplimab (Libtayo) - NCBI Bookshelf
CADTH recommends that Libtayo in combination with platinum-based chemotherapy be reimbursed by public drug plans for the first-line treatment of adults with non–small cell lung cancer (NSCLC) whose tumours have no EGFR, ALK, or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or for those with metastatic NSCLC, if
|
|
|